Discontinuation report LARTRUVO
| Report ID | 124196 |
| Drug Identification Number | 02480271 |
| Brand name | LARTRUVO |
| Common or Proper name | OLARATUMAB |
| Company Name | ELI LILLY CANADA INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | OLARATUMAB |
| Strength(s) | 190MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS |
| Packaging size | 1 Vial, 190 MG / 19 ML |
| ATC code | L01XC |
| ATC description | |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2020-10-22 |
| Actual discontinuation date | 2020-09-25 |
| Remaining supply date | 2020-09-25 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | Lilly Canada’s Customer Response Centre 1-888-545-5972. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | EXCHANGE TOWER, 130 KING STREET WEST TORONTO, ONTARIO CANADA M5X 1B1 |
| Company contact information | Lilly Canada’s Customer Response Centre 1-888-545-5972. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2020-10-05 | French | Compare |
| v3 | 2020-10-05 | English | Compare |
| v2 | 2020-09-14 | French | Compare |
| v1 | 2020-09-14 | English | Compare |
Showing 1 to 4 of 4